Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Clin Transplant ; 28(5): 546-53, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24579925

RESUMO

Transplant glomerulopathy (TG) is associated with poor long-term allograft survival and is often accompanied by microcirculation inflammation. Histopathologic scoring may inform prognosis and help guide therapy. We retrospectively assessed 33 patients with biopsy-proven TG. All biopsies were given a glomerulitis (g) and peritubular capillaritis (ptc) score. We determined allograft survival and serum creatinine stability in three different score groups: g < 2 and ≥ 2, ptc < 2 and ≥ 2, and (g + ptc) < 4 and ≥ 4. We assessed the impact of treatment with intravenous immune globulin (IVIG) and rituximab on outcomes. Graft survival and serum creatinine stability did not differ in each of the histopathologic score groups. Higher-score groups were associated with the presence of concomitant antibody-mediated rejection and were more likely to receive IVIG and rituximab. Treatment with IVIG and rituximab resulted in stability of serum creatinine within the higher-score groups, but not in the lower-score groups. Stabilization of serum creatinine was associated with an improvement in donor-specific antibody. Histopathologic scoring in kidney allograft biopsies with TG may help guide treatment. The combination of IVIG and rituximab appears to be beneficial in patients whose biopsies have moderate or severe microvascular injury.


Assuntos
Anticorpos Monoclonais Murinos/administração & dosagem , Glomerulonefrite/patologia , Rejeição de Enxerto/patologia , Imunoglobulinas Intravenosas/administração & dosagem , Inflamação/patologia , Nefropatias/complicações , Transplante de Rim/efeitos adversos , Seguimentos , Glomerulonefrite/etiologia , Rejeição de Enxerto/tratamento farmacológico , Rejeição de Enxerto/etiologia , Sobrevivência de Enxerto/efeitos dos fármacos , Humanos , Fatores Imunológicos/administração & dosagem , Inflamação/tratamento farmacológico , Inflamação/etiologia , Nefropatias/patologia , Nefropatias/cirurgia , Prognóstico , Estudos Retrospectivos , Fatores de Risco , Rituximab , Taxa de Sobrevida , Transplante Homólogo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa